anti-*T. gondii* IgG in oral fluid. It was then applied to 150 children aged 0–15 months (341 samples) born from 133 women who seroconverted during pregnancy and 17 who remained seronegative. IgG on oral fluid were compared to serum IgG detected with MEIA AxSYM® Toxo IgG (Abbott Laboratories).

Results The pilot study validated the acceptability and the safety of the test and the adequate duration of sampling. IgG detected in serum and in oral fluid had a parallel kinetics among newborns (correlation coefficient: 0.59, $p < 0.0001$), with a concordant decline in the non-infected ones ($n = 110$), and matching raising or stable IgG in those who were congenitally-infected ($n = 23$).

Conclusions Collection of oral fluid is painless and inexpensive. Our new test provides a simple and rapid method to detect anti-*Toxoplasma gondii* IgG and to manage newborn at risk for congenital infection. It could have many other applications in pregnant women and other groups of patients.

PO-0384 THE PRACTICAL METHOD TO DIAGNOSIS OF FOURTEEN CASES OF GLYCOGEN STORAGE DISEASES IN OUR LABORATORY

L Yargui, N Gagi, M Djeddou, N Atia, S Gacem, A Berhoune. *Medicine, CHU Mustapha Bacha, Algiers, Algeria*

10.1136/archdischild-2014-307384.1030

Glycogen storage diseases (GSD) are a group of inherited disorders of metabolism that result in storage of excess glycogen. Several well defined defects in one of the enzymes involved in the synthesis or degradation of glycogen have been described. There are over 15 types and they are classified based on the enzyme deficiency and the affected tissue (liver, muscle or both).

In this study, we wish to report the biochemical investigations adopted in main infantile GSD diagnosed in our laboratory.

Four steps diagnostic procedure have been assumed, taking into account several frequent clinical observations leading to further targeted biochemical parameters:

1. Assessment of the metabolic disorders with standard tests (fast blood glucose, uric acid, triglycerides, total cholesterol, ASAT, ALAT, CK, lactic acid).

2. Quantitative determination of glycogen in leucocytes (or erythrocytes) after extraction, precipitation and treatment with an throne reagent.

3. Oral galactose test with blood lactate and glucose estimations, in combination with a glucagon tolerance test to screen the main types of liver glycogenosis.

4. Lysosomal acid α -glucosidase activity when GSD type II (Pompe disease) is suspected.

Since 1995 and on the basis of this screening procedure and clinical features, 14 cases of GSD have been categorised:

- 6 forbes's disease (GSD III, debranching-enzyme deficiency)
- 3 von Gierke's disease (GSD I, glucose-6-phosphatase deficiency)
- 2 pompe's disease (GSD II, maltase acid deficiency)
- 1 Andersen's disease (GSD IV, branching-enzyme deficiency)
- 1 Hers's disease (GSD VI, hepatic phosphorylase deficiency)
- 1 GSD IX (phosphorylase kinase deficiency)

Our laboratory diagnostic approach include simple screening tests easy to implement in clinical chemistry laboratories. Thus, Pompe disease diagnosis is easily done in our laboratory. The measurement of tissue enzyme activities (liver and muscle) of the other enzymes is limited to some specialised laboratories. The molecular diagnosis offers a good alternative for GSD type 0, I and III but requires better financial means.

PO-385 WITHDRAWN

Miscellaneous

PO-0385a ADVERSE CHILDHOOD EXPERIENCES IN ALBERTA, CANADA: A POPULATION BASED STUDY

¹S McDonald, ²D Kingston, ¹S Tough. ¹Pediatrics, University of Calgary, Calgary, Canada; ²Nursing, University of Alberta, Edmonton, Canada

10.1136/archdischild-2014-307384.1031

Objective Adverse childhood experiences (ACEs) are associated with poor health outcomes in adulthood. We developed ACE risk profiles using a domain-specific approach and examined ACEs as risk factors for diagnosed physical and mental health conditions.

Method A computer-assisted telephone survey was conducted with a random sample of adults in Alberta, Canada. Eight questions were asked on adversity during childhood, based on the original ACE survey and modified to reflect the Canadian context and research methodology. Descriptive and multivariable analyses were conducted.

Results Among the 1207 respondents, the majority were married or living common-law (65.8%), had completed post-secondary education (78.2%), and were Caucasian (86.2%) with a mean age of 52.4 years (SD=16.3). Approximately one-third (27.3%) experienced at least one type of abuse, and almost half (49.5%) experienced at least one form of household dysfunction. ACEs were highly interrelated. Sixty-three percent fell into the low risk profile, with the remaining 37% divided among the three higher risk profiles. Overall, ACE risk profile was significantly associated with diagnosed mental health condition/addiction and chronic pain, controlling for sociodemographic characteristics.

Conclusion The ACE risk profile of ACEs in both the abuse domain and the household dysfunction domain conferred the greatest risk for poor health outcomes in adulthood. Given the interrelated of ACEs, a more comprehensive approach to conceptualization of ACEs is warranted. Results have implications for prevention of ACEs and recovery from ACEs to decrease disease burden. Strategies may include effective programs to prevent exposure to toxic stress and support nurturing and stable relationships for children and families.

Neonatal Brain and Development

PO-0386 NEONATAL SEIZURES ON AEEG MONITORING AFTER IN UTERO EXPOSURE TO VENLAFAXINE

¹A Ansary, ²SE Ibhaneesebor, ²CM Manjunatha. ¹Paediatrics, Royal Alexandra Hospital, Paisley, UK; ²Neonatology, Wishaw General Hospital, Wishaw, UK

10.1136/archdischild-2014-307384.1032

We report an unusual presentation of withdrawal from venlafaxine in a preterm baby of 29 weeks gestation, who presented with myoclonic seizures on second day of life. The seizures were confirmed with amplitude integrated EEG (aEEG). Other causes of neonatal seizures were excluded. She responded to treatment with phenobarbitone and phenytoin. Her MRI scan of the brain was normal and remains well on follow up. We believe this case to be the first report of seizure in a preterm baby resulting from maternal venlafaxine use and details the contribution of aEEG in the care of one such infant.